Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-06-07
2002-04-02
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S496000
Reexamination Certificate
active
06365585
ABSTRACT:
The subject of the invention is metabolites of the products of formula I, and compounds of formula II and formula III below.
1. Field of the Invention
The present invention relates to [1,4]diazepino-[6,7,1-hi]indoles, and to those for the preparation of medicaments that enable treatment of affections which are amenable to therapy by a phosphodiesterase IV inhibitor. These medicaments are useful, in particular, as anti-inflammatories, anti-allergics, bronchodilators or anti-asthmatics and are devoid of digestive or cardiac side-effects.
2. Technological Background of the Invention
WO-A-9611690 describes [1,4]diazepino[6,7,1-hi]indoles, including in particular (3R)-N-(9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indol-3-yl)isonicotinamide. (which will be abbreviated to MPTDI in the text which follows).
SUMMARY OF THE INVENTION
The subject of the invention is metabolites of the products of formula I and of the products of formula II or III below.
DETAILED DESCRIPTION OF THE INVENTION
In a first aspect, the invention relates to the metabolites of the products of formula (I):
in which:
R is a lower alkyl or alkoxy;
A is aryl, nitrogen-containing heteroaryl or sulphur-containing heteroaryl, each optionally substituted with one to three groups independently chosen from halogen, lower alkyl, haloalkyl, lower alkoxy, hydroxyl, acetoxy, amino, t-butoxycarbonylamino, cycloalkylcarbonylamino or acetamido; of their racemic forms, of their isomers having a configuration which is determined by the carbon at the 3-position of the diazepinoindol-4-one ring, and of their pharmacologically acceptable salts.
Preferably, R is a methyl group.
Preferably, the asymmetric carbon has the R configuration.
Preferably, the product of formula I is the product N-(9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-3-yl)isonicotinamide, advantageously the configuration is 3R.
This term <<metabolite>> covers these products derived from biodegradation by a mammal, in particular humans, of the said products of formula I.
The, preferred metabolites are those which are oxidized and/or hydroxylated, on the substituents and/or the rings and/or heterocycles.
In particular, the invention relates to the metabolites corresponding to the derivatives which are hydroxylated on the pyrrolidine or 1-phenylbenzodiazepine ring.
Advantageously, the products are those in which A is pyridyl, optionally N-oxidized.
In a second aspect, the invention relates to the diazepinoindoles of formula (II)
in which:
Z is a lower alkyl or alkoxy;
A is aryl, nitrogen-containing heteroaryl or sulphur-containing heteroaryl, each optionally substituted with one to three groups independently chosen from halogen, lower alkyl, haloalkyl, lower alkoxy, hydroxyl, acetoxy, amino, t-butoxycarbonylamino, cycloalkylcarbonylamino or acetamido, the N-oxide or S-oxide forms;
Y is hydroxyl or lower alkoxy;
n is 1 or 2.
of their racemic forms, of their isomers having a configuration which is determined by the carbon at the 3-position of the diazepinoindol-4-one ring, and of their pharmacologically acceptable salts.
Preferably, Y is hydroxyl or methoxy.
The phenyl is preferably substituted at the para-position, advantageously with a hydroxyl.
Advantageously, the products are those in which A is pyridyl, optionally N-oxidized.
Among the diazepinoindoles of formula (II), those in which the asymmetric carbon atom at the alpha-position with respect to the carbonyl of the diazepine ring has the absolute configuration (R), are preferred.
Examples of such products are reproduced below:
In a third aspect, the invention relates to the diazepinoindoles of formula (III)
in which:
Z′ is hydroxymethyl, formyl, carboxylic acid in its free form, salified, esterified or amidated, hydroxymethyl whose hydroxyl group is esterified;
A′ is aryl, nitrogen-containing heteroaryl or sulphur-containing heteroaryl, each optionally substituted with one to three groups independently chosen from halogen, lower alkyl, haloalkyl, lower alkoxy, hydroxyl, acetoxy, amino, t-butoxycarbonylamino, cycloalkylcarbonylamino or acetamido, the N-oxide or S-oxide forms;
Y′ is hydroxyl or lower alkoxy;
n′ is 0, 1 or 2.
of their racemic forms, of their isomers having a configuration which is determined by the carbon at the 3-position of the diazepinoindol-4-one ring, and of their pharmacologically acceptable salts.
Preferably, Z′ is chosen from the group consisting of hydroxymethyl; formyl; COOH; CONH
2
, COOD where D is a lower alkyl, optionally hydroxylated; —CH
2
—O—C(O)—E where E is a lower alkyl, an aryl, cycloalkyl, or pyridyl.
Preferably, Y′ is hydroxyl or methoxy.
The phenyl is preferably substituted at the para-position, advantageously with a hydroxyl. Among the diazepinoindoles of formula (III), those in which the asymmetric carbon atom at the alpha-position with respect to the carbonyl of the diazepine ring has the absolute configuration (R), are preferred.
Advantageously, the products are those in which A′ is pyridyl, optionally N-oxidized.
Examples of such products are reproduced below:
In the foregoing as well as hereinafter:
aryl is understood to mean a phenyl or naphthyl group;
nitrogen- or sulphur-containing heteroaryl is understood to mean an unsaturated monocyclic or polycyclic group containing at least one nitrogen or sulphur atom, respectively, and preferably these heterocycles may be four- to seven-membered heteromonocyclic groups containing from 1 to 4 heteroatoms, or unsaturated fused heterocyclic groups containing from 1 to 4 heteroatom; the heteroaryl group may be methylated or ethylated on a positively charged nitrogen;
halogen is understood to mean fluorine, chlorine, bromine or iodine;
lower alkyl is understood to mean linear or branched alkyl groups containing from one to four carbon atoms;
cycloalkyl is understood to mean cyclopropyl, cyclobutyl and cyclopentyl groups;
lower alkoxy is understood to mean an O-alkyl group in which the alkyl group is a lower alkyl as defined above;
haloalkyl is understood to mean a mono-, di- or trihaloalkyl containing from 1 to 4 carbon atoms.
A review of salts which are acceptable in pharmacy will be found in J. Pharm. Sci., 1977, 66, 1-19. However, pharmacologically acceptable salt of a compound of formula (I) possessing a basic portion is understood to mean the addition salts of the compounds of formula (I) which are formed from nontoxic inorganic or organic acids such as, for example, the salts of hydrobromic, hydrochloric, sulphuric, sulphamic, phosphoric, nitric, acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, mucic, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulphanilic, acetoxybenzoic, fumaric, toluenesulphonic, ethanedisulphonic, oxalic, isethionic and the like, acids. The various quaternary ammonium salts of the derivatives (I) are also included in this category of the compounds of the invention. And pharmacologically acceptable salt of a compound of formula (I) possessing an acidic portion is understood to mean the commonplace salts of the compounds of formula (I) which are formed from nontoxic inorganic or organic bases such as, for example, alkali metal and alkaline-earth metal hydroxides (lithium, sodium, potassium, magnesium and calcium hydroxides), amines (dibenzylethylenediamine, trimethylamine, piperidine, pyrrolidine, benzylamine and the like) or alternatively quaternary ammonium hydroxides such as tetramethylammonium hydroxide.
The invention also relates to the above products as a medicament, and in particular for combating inflammatory diseases, allergic diseases and bronchoconstriction, or which is useful in the treatment of asthma, characterized in that it comprises a diazepinoindole according to the invention, in a pharmaceutical dosage form which is suited to the disease to be treated. The invention also relates to the use of the above products for the preparation of
Jacobelli Henry
Julien-Larose Christine
Marc Sylvie
Ashbrook Charles W.
Kifle Bruck
Purchase, Jr. Claude F.
Warner-Lambert & Company
LandOfFree
Phosphodiesterase IV-inhibiting diazepinoindoles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphodiesterase IV-inhibiting diazepinoindoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphodiesterase IV-inhibiting diazepinoindoles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2861085